[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593829":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":25,"interventions":36,"overallOfficials":46,"centralContacts":51,"locations":57,"responsibleParty":74,"collaborators":13,"id":76,"slug":13,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":13,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":13,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":13,"overallStatus":59,"whyStopped":13,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Change from the baseline in Forced Expiratory Volume in one second (FEV1)","Change from baseline in pre-bronchodilator FEV1 in each dose group at 12 weeks of CM512 treatment compared with placebo.","Up to week 12",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[26,31],{"label":27,"type":28,"description":13,"interventionNames":29},"Group 1","EXPERIMENTAL",[30],"Biological: CM512 injection",{"label":32,"type":33,"description":13,"interventionNames":34},"Group 2","PLACEBO_COMPARATOR",[35],"Drug: Placebo",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":13},"BIOLOGICAL","CM512 injection","subcutaneous injection",[27],{"type":43,"name":44,"description":40,"armGroupLabels":45,"otherNames":13},"DRUG","Placebo",[32],[47],{"name":48,"affiliation":49,"role":50},"Ruchong Chen","The First Clinical Hospital of Guangzhou Medical University","PRINCIPAL_INVESTIGATOR",[52],{"name":53,"role":54,"phone":55,"phoneExt":13,"email":56},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[58],{"facility":49,"status":59,"city":60,"state":61,"zip":13,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":65,"coordinates":66},"Point",[67,68],113.25,23.11667,{"lat":68,"lon":67},[71],{"name":48,"role":54,"phone":72,"phoneExt":13,"email":73},"13710723826","chen_rch@163.com",{"type":75,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100593829",false,"NCT07011524","Study of CM512 Injection in Subjects With Moderate-to-severe Asthma","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.","Inclusion Criteria:\n\n* Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form.\n* Age ≥ 18 years old and ≤ 75 years old.\n* Body mass index (BMI) ≥ 18.0 kg\u002F(m\\*m).\n* Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1.\n* Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.\n* Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5\n\nExclusion Criteria:\n\n* Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating.\n* With a history of drug abuse within the past 5 years before screening visit.\n* Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock.\n* With any medical or non-medical conditions that are not suitable for participation in this study by investigators.","ALL","18 Years","75 Years",{"count":86,"type":87},200,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.",[93],"Asthma","2025-08-21",{"date":96,"type":97},"2025-08-28","ACTUAL",{"date":99,"type":97},"2025-08-19",{"date":101,"type":87},"2027-07-21",{"name":5,"class":6},1]